dendritic cells (dcs) are professional antigen presenting cells that have a potential role in the initiating of immune responses. the cell vaccination is a new strategy in treatment of infectious diseases and cancers. in this study, we have generated monocyte-derived dendritic cells of lymphoma patient's peripheral blood mononuclear cells then; these cells were used as vaccine in lymphoma patie...

Background: Lymphoma is a malignant proliferation of lymphoid cells. External T-cell lymphoma is very rare. Lymphomas are neoplastic growth of lymphocytes caused by organisms like EBV, HIV, etc. This malignancy is classified as Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. Oral lymphomas account for a small percentage of head and neck malignancies, and intraoral lymphoma is rare and mostly see...

Background: Non-Hodgkin’s lymphoma (NHLs) is known as a heterogeneous group of malignant lymphoproliferative disorders. NHLs are classified into B cell and T cell types. Immunophenotypical assessment of the biopsy specimens can help diagnose NHLs.    Methods: In this study, 77 patients with B cell and T cell lymphoma were selected from Shahid Sadoghi hospital during 2010 to 2...

Uterine lymphoma is a rare disease therefore, information regarding histologic type, immunophenotype of tumor cells and etiologic factors are limited. although secondary involvement of the genital tract occurs in up to 40% of cases• of disseminated lymphoma, lymphoma presenting with primary female genital tract . symptomatology is very unusual. We report a case of B-cell lymphoma in the ut...

malignant lymphoma is the neoplastic transformation of cells, mostly originating from lymphoid tissues. malignant lymphoma has two major subtypes: hodgkin and non-hodgkin lymphoma. malignant lymphoma is the most common neoplasm in 3rd and 4th decades of life and more than two third of affected patients presented painless peripheral lymphadenopathy. involvement of waldeyer’s ring, epitrochlear a...

Most B-cell malignancies are dependent upon signaling by the Bcell receptor (BCR) and other growth and survival signals provided by the tumor microenvironment. Two recently US Food and Drug Administration–approved drugs that target the BCR signalosome, the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, and the phosphatidylinositol 3-kinase d (PI3Kd) inhibitor idelalisib, show unprecedented c...